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Case Report of Restoration of the
Corneal Epithelium in a Patient with
Atopic Keratoconjunctivitis Resulting
in Amelioration of Ocular Allergic
Inflammation
Ken Fukuda1,2, Naoyuki Yamada1 and Teruo Nishida1
ABSTRACT
Background: Atopic and vernal keratoconjunctivitis are severe types of ocular allergic disease characterized
not only by conjunctival inflammation but also by corneal involvement. In vitro studies have suggested that
breakdown of corneal epithelial barrier function and subsequent activation of stromal fibroblasts may amplify
ocular allergic inflammation.
Case Summary: A 27-year-old man with atopic dermatitis developed atopic keratoconjunctivitis including cor-
neal ulcer with plaque deposition in his right eye. Conjunctival inflammation in the right eye was resistant to
topical steroid therapy. Surgical removal of corneal plaque and administration of autologous fibronectin eye-
drops resulted not only in resurfacing of the corneal epithelium but also in amelioration of conjunctival inflam-
mation.
Discussion: This case suggests that loss of corneal epithelial integrity likely exacerbates conjunctival allergic
inflammation and that restoration or maintenance of the barrier function of the corneal epithelium may be one of
the important targets for the treatment of severe ocular allergic diseases.
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INTRODUCTION
Atopic keratoconjunctivitis (AKC) and vernal kerato-
conjunctivitis (VKC) are severe types of ocular aller-
gic disease that are characterized by chronic inflam-
mation of the conjunctiva and various corneal epithe-
lial disorders including superficial punctate keratopa-
thy, epithelial defects, shield ulcer, and plaque.1 Per-
sistence of these corneal lesions can result in the de-
velopment of complications such as scarring, corneal
vascularization, amblyopia, and infectious keratitis
and a consequent reduction in visual acuity. These
corneal lesions are often resistant to therapy, how-
ever, and remain a challenge in the treatment of ocu-
lar allergy.2
The pathogenesis of corneal lesions is thought to
involve a combination of toxic epitheliopathy due to
eosinophil- and mast cell-derived inflammatory me-
diators as well as mechanical damage to the corneal
epithelium by giant papillae. The fact that the severity
of conjunctival inflammation and corneal lesions in in-
dividuals with AKC or VKC often differs between the
right and left eyes and the difficulty of treatment for
conjunctivitis with corneal lesions suggest that local
factors and interaction between conjunctival inflam-
mation and corneal lesions may contribute to the ex-
aggeration of ocular allergic inflammation. We now
report a case of AKC that was successfully treated by
restoration of the corneal epithelium.
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Fig. 1 Slitlamp photographs of the eyes of the patient. Whereas the left eye of the patient appeared normal (A), marked swel
ling and redness in the palpebral and bulbar conjunctiva as wel as corneal epithelial defects with plaque deposition were ob
served in the right eye before surgery (B). Conjunctival redness and sweling in the right eye were diminished after corneal 
epithelial resurfacing (C).





The patient was a 27-year-old Japanese man with cor-
neal ulcer and plaque in his right eye. His AKC had
been managed for several years at another eye clinic
by application of topical corticosteroids and antibiotic
eyedrops. On 13 April 2004, the patient was referred
to our hospital because of the persistence of corneal
plaque for 9 months despite the use of topical ther-
apy. At his first visit to our hospital, his best cor-
rected visual acuity was 0.4 in the right eye and 1.2 in
the left eye. Slitlamp examination revealed lid swel-
ling and redness in the bulbar and palpebral conjunc-
tiva of the right eye. Corneal epithelial defects with
plaque deposition and superficial vascular invasion
were also apparent in the right cornea (Fig. 1). Con-
junctival inflammation and corneal disorders were not
observed in the left eye. The patient had also experi-
enced atopic dermatitis for more than 15 years. He
had a history of herpetic keratitis in both eyes dating
back about 18 months.
PATHOLOGICAL FINDINGS
Laboratory analysis showed a high level of immuno-
globulin E (5110 IUml) in the patient’s serum (nor-
mal range, 0 to 120 IUml). Hansel staining also re-
vealed the presence of eosinophils in discharge from
his right eye. We diagnosed AKC with corneal ulcer
and plaque deposition. We prescribed continued use
of eyedrops containing betamethasone sodium phos-
phate four times a day and added subconjunctival in-
jection of dexamethasone twice a week. However,
conjunctival inflammation and the corneal epithelial
defects had not improved after 1 month, so we of-
fered surgical intervention for removal of the persis-
tent corneal plaque. Removal of the plaque with a
spatula was performed with the patient under local
anesthesia induced by xylocaine eyedrops. In addi-
tion to the betamethasone sodium phosphate eye-
drops, we then prescribed administration four times a
day of eyedrops containing fibronectin isolated from
the patient’s own blood3 in order to promote epithe-
lial wound healing. Three weeks after surgery, com-
plete epithelialization of the cornea had occurred and
the lid swelling and redness in the bulbar and palpe-
bral conjunctiva were also diminished (Fig. 1). Visual
acuity of the right eye had improved to 0.6. Corneal
erosion and conjunctival inflammation had not re-
curred within 2 months after epithelialization under
treatment with fluorometholone and sodium cromo-
glicate eyedrops.
DISCUSSION
Corneal lesions are thought to be induced by the se-
vere conjunctival inflammation in patients with AKC
or VKC, with surgical removal of giant papillae at the
palpebral conjunctiva having been found to be effec-
tive for treatment of corneal lesions in individuals
with VKC.2,4 On the other hand, the effect of persis-
tence of corneal epithelial defects on conjunctival in-
flammation has been unclear. We have now pre-
sented a case of AKC in which conjunctival inflamma-
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tion was suppressed as a result of restoration of the
corneal epithelium through surgical removal of
plaque and the administration of fibronectin eye-
drops. This case therefore suggests that loss of the
integrity of the corneal epithelium may amplify aller-
gic inflammation in severe ocular allergic diseases.
Corneal plaque formed at the base of a shield ulcer
prevents epithelialization of the cornea, does not re-
solve spontaneously, and is not usually affected by
pharmacological therapy. It is usually removed by
surgery in order to promote epithelial resurfacing.2,5
Before surgical removal of the plaque, conjunctival in-
flammation should be adequately controlled in order
to prevent plaque recurrence before epithelialization.
The present case was not affected by topical corti-
costeroid therapy, however, and the patient was not a
candidate for resection of the palpebral conjunctiva
because of the lack of giant papillae. Oral corticoster-
oids might have been able to suppress the conjuncti-
val inflammation in the patient, but he did not want to
undergo such treatment because of the possible side
effects. Although we were not able to use topical im-
munosuppressants because of their unavailability at
the time, eyedrops containing cyclosporine A or
tacrolimus are now available in Japan. Topical admini-
stration of these immunosuppressants has recently
been found to be effective for the treatment of VKC
or AKC, with such an approach now representing an-
other therapeutic option.6,7
Fibronectin is a glycoprotein that is present in
plasma and the extracellular matrix and is responsi-
ble for cellular adhesion and migration.8 We have pre-
viously shown that eyedrops containing fibronectin
isolated from a patient’s own plasma are effective for
treatment of corneal epithelial erosion associated
with various ocular surface diseases.9-11 We have also
demonstrated the effectiveness of fibronectin eye-
drops for promotion of corneal epithelial wound heal-
ing after the removal of corneal plaque in patients
with VKC.12 Although conjunctival inflammation was
not controlled before surgery in the present case, the
epithelial defects disappeared completely without re-
deposition of plaque after the administration of au-
tologous fibronectin eyedrops and eyedrops contain-
ing betamethasone sodium phosphate. Betametha-
sone might have penetrated the corneal stroma after
removal of the plaque and may have suppressed the
function of corneal fibroblasts, including their expres-
sion of chemokines, thereby contributing to the ame-
lioration of ocular allergic inflammation. This case
also suggests that, although topical fibronectin by it-
self does not suppress inflammation, it might be ef-
fective for promoting corneal epithelial wound heal-
ing and consequent suppression of conjunctival in-
flammation.
On the basis of in vitro experiments, we and others
have shown that fibroblasts of the corneal stroma, but
not corneal epithelial cells, act as amplifiers of ocular
allergic inflammation by expressing chemokines and
adhesion molecules.13-15 The barrier function of the
corneal epithelium may suppress allergic inflamma-
tion by preventing the penetration of inflammatory
mediators present in tear fluid into the corneal
stroma. We have also recently shown that the con-
junctiva and cornea interact in a reciprocal manner in
a rat model of allergic conjunctivitis; the presence of
corneal epithelial defects exacerbated conjunctival
eosinophilia whereas conjunctival eosinophilic inflam-
mation suppressed corneal epithelial wound healing,
suggestive of the operation of a vicious cycle.16 To-
gether with the present case, these observations sug-
gest that restoration or maintenance of the corneal
epithelial barrier may be one of the important targets
for the treatment of severe ocular allergic diseases.
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